| Bortezomib | Approved Investigational | TMEM55B | 90809 |
downregulated | Bortezomib results in decreased expression of TMEM55B mRNA | 14q11.2 | |
| Bortezomib | Approved Investigational | TMEM92 | 162461 |
downregulated | Bortezomib results in decreased expression of TMEM92 mRNA | 17q21.33 | |
| Bortezomib | Approved Investigational | TMPO | 7112 |
downregulated | Bortezomib results in decreased expression of TMPO mRNA | 12q23.1 | |
| Bortezomib | Approved Investigational | TNFAIP3 | 7128 |
upregulated | [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TNFAIP3 mRNA | 6q23.3 | |
| Bortezomib | Approved Investigational | TNFAIP8L1 | 126282 |
downregulated | [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of TNFAIP8L1 mRNA | 19p13.3 | |
| Bortezomib | Approved Investigational | TNFRSF10B | 8795 |
upregulated | Bortezomib results in increased expression of TNFRSF10B mRNA | 8p21.3 | |
| Bortezomib | Approved Investigational | TNFRSF9 | 3604 |
upregulated | [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TNFRSF9 mRNA | 1p36.23 | |
| Bortezomib | Approved Investigational | TNFSF10 | 8743 |
downregulated | Bortezomib results in decreased expression of TNFSF10 mRNA | 3q26 | |
| Bortezomib | Approved Investigational | TNKS | 8658 |
downregulated | [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of TNKS mRNA | 8p23.1 | |
| Bortezomib | Approved Investigational | TOR1AIP1 | 26092 |
downregulated | Bortezomib results in decreased expression of TOR1AIP1 mRNA | 1q25.2 | |
| Bortezomib | Approved Investigational | TPI1 | 7167 |
upregulated | Bortezomib results in increased expression of TPI1 mRNA | 12p13.31 | |
| Bortezomib | Approved Investigational | TPM1 | 7168 |
upregulated | Bortezomib results in increased expression of TPM1 mRNA | 15q22.2 | |
| Bortezomib | Approved Investigational | TRA2A | 29896 |
downregulated | Bortezomib results in decreased expression of TRA2A mRNA | 7p15.3 | |
| Bortezomib | Approved Investigational | TRAFD1 | 10906 |
upregulated | Bortezomib results in increased expression of TRAFD1 mRNA | 12q24.13 | |
| Bortezomib | Approved Investigational | TRIB3 | 57761 |
upregulated | [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TRIB3 mRNA | 20p13 | |
| Bortezomib | Approved Investigational | TRIM65 | 201292 |
downregulated | Bortezomib results in decreased expression of TRIM65 mRNA | 17q25.1 | |
| Bortezomib | Approved Investigational | TRIML2 | 205860 |
upregulated | [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TRIML2 mRNA | 4q35.2 | |
| Bortezomib | Approved Investigational | TRIO | 7204 |
downregulated | Bortezomib results in decreased expression of TRIO mRNA | 5p15.2 | |
| Bortezomib | Approved Investigational | TRRAP | 8295 |
downregulated | Bortezomib results in decreased expression of TRRAP mRNA | 7q22.1 | |
| Bortezomib | Approved Investigational | TSEN15 | 116461 |
downregulated | Bortezomib results in decreased expression of TSEN15 mRNA | 1q25.3 | |
| Bortezomib | Approved Investigational | TTC39A | 22996 |
upregulated | Bortezomib results in increased expression of TTC39A mRNA | 1p32.3 | |
| Bortezomib | Approved Investigational | TTC7A | 57217 |
downregulated | Bortezomib results in decreased expression of TTC7A mRNA | 2p21 | |
| Bortezomib | Approved Investigational | TTL | 150465 |
downregulated | Bortezomib results in decreased expression of TTL mRNA | 2q14.1 | |
| Bortezomib | Approved Investigational | TTPAL | 79183 |
downregulated | Bortezomib results in decreased expression of TTPAL mRNA | 20q13.12 | |
| Bortezomib | Approved Investigational | TUBB2A | 7280 |
upregulated | Bortezomib results in increased expression of TUBB2A mRNA | 6p25.2 | |